BIO Bio-Rad Laboratories, Inc. Class A

Price (delayed)

$513.48

Market cap

$15.24B

P/E Ratio

7.85

Dividend/share

N/A

EPS

$65.39

Enterprise value

$15.28B

Sector: Healthcare
Industry: Medical Devices
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Highlights

The EPS has soared by 116% YoY and by 24% from the previous quarter
The net income has soared by 115% YoY and by 23% QoQ
The company's quick ratio has shrunk by 50% YoY and by 7% QoQ

Key stats

What are the main financial stats of BIO
Market
Shares outstanding
29.68M
Market cap
$15.24B
Enterprise value
$15.28B
Valuations
Price to earnings (P/E)
7.85
Price to book (P/B)
2.07
Price to sales (P/S)
6.64
EV/EBIT
6.03
EV/EBITDA
6.03
EV/Sales
6.66
Earnings
Revenue
$2.29B
EBIT
$2.53B
EBITDA
$2.53B
Free cash flow
$322.16M
Per share
EPS
$65.39
Free cash flow per share
$10.86
Book value per share
$248.02
Revenue per share
$77.35
TBVPS
$323.57
Balance sheet
Total assets
$10.1B
Total liabilities
$2.74B
Debt
$645.78M
Equity
$7.35B
Working capital
$1.21B
Liquidity
Debt to equity
0.09
Current ratio
2.3
Quick ratio
1.52
Net debt/EBITDA
0.02
Margins
EBITDA margin
110.4%
Gross margin
54.4%
Net margin
84.9%
Operating margin
10.6%
Efficiency
Return on assets
22.9%
Return on equity
31.7%
Return on invested capital
34.6%
Return on capital employed
27.6%
Return on sales
110.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.29B
Gross profit
$1.25B
Operating income
$242.78M
Net income
$1.95B
Gross margin
54.4%
Net margin
84.9%
The net income has soared by 115% YoY and by 23% QoQ
The net margin has surged by 115% year-on-year and by 25% since the previous quarter

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
P/E
7.85
P/B
2.07
P/S
6.64
EV/EBIT
6.03
EV/EBITDA
6.03
EV/Sales
6.66
The EPS has soared by 116% YoY and by 24% from the previous quarter
The price to earnings (P/E) is 91% lower than the 5-year quarterly average of 86.8 and 32% lower than the last 4 quarters average of 11.5
The equity has grown by 34% YoY and by 17% from the previous quarter
BIO's P/B is 15% above its last 4 quarters average of 1.8 and 9% above its 5-year quarterly average of 1.9
The stock's price to sales (P/S) is 95% more than its 5-year quarterly average of 3.4 and 36% more than its last 4 quarters average of 4.9

Efficiency

How efficient is Bio-Rad Laboratories business performance
The ROS has soared by 106% YoY and by 25% from the previous quarter
Bio-Rad Laboratories's ROA has soared by 70% YoY and by 15% from the previous quarter
The ROE has soared by 69% year-on-year and by 14% since the previous quarter
The company's return on invested capital has surged by 66% YoY and by 16% QoQ

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The company's current ratio has shrunk by 51% YoY and by 4.2% QoQ
The company's quick ratio has shrunk by 50% YoY and by 7% QoQ
The debt is 91% smaller than the equity
The equity has grown by 34% YoY and by 17% from the previous quarter
Bio-Rad Laboratories's debt to equity has decreased by 25% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.